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ABSTRACT
With the increasing use of progenitor cell transplantation in older patients defining predictors of outcomes in
this patient population will be important to guarantee the appropriate use of this procedure. Comorbidity
assessments are not sufficiently sensitive in determining outcomes, functional assessment tools such as those
used in rehabilitation medicine could be useful not only in predicting outcomes, but as another dimension of
quality of life. These tools have rarely been used in the setting of hematopoietic progenitor cell transplantation.
In this session we will review current trends in predicting transplant outcomes, the use of functional assesment
tools in predicting morbidity post medical interventions, as well as potential strategies of improving functional
status using growth hormone agonists.
© 2007 American Society for Blood and Marrow Transplantation
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Predicting risk of treatment-related toxicities in pa-
ients undergoing high-dose chemotherapy with pro-
enitor cell support has always been an integral part of
he decision process for physicians and patients involved
n this procedure. Initially, when the procedure was used
nly as salvage therapy for patients with advanced dis-
ase, performance status and age were the most common
actors taken into consideration when deciding whether
r not to proceed to high-dose chemotherapy.
With the increasing use of progenitor cell trans-
lantation because of previous use of the procedure
nd advancing age of the transplant recipient, more
ttention is being paid to variables or pretransplant
actors that can predict transplantation outcomes.
In the ﬁrst part of this session, Dr Giralt summarizes
he value of current pretransplantation assessment in
redicting transplantation outcomes, the value of co-
orbidity scores, and novel ways of measuring trans-
lantation toxicities and outcomes. In the second part,
r Simmonds describes commonly used functional as-
essment tools used in healthy and sick individuals and
heir potential role as pretransplantation assessment b
8ools. In the ﬁnal part of this session, Dr Smith summa-
izes current strategies being used in the setting of geri-
tric medicine and rehabilitation medicine aimed at re-
toring or improving functional status and discuss their
otential application in the setting of high-dose therapy
nd progenitor cell transplantation.
REDICTING TRANSPLANTATION OUTCOMES—CURRENT
RENDS AND HISTORICAL PERSPECTIVES
Pretransplantation single-organ function has been
he most frequently studied pretransplantation vari-
ble used to predict outcome. In a recent review of
uch studies by Bolwell [1], the most important con-
lusions were that pretransplantation cardiopulmo-
ary testing did not reliably predict for adverse out-
omes but that pretransplantation abnormal liver
unctions tests were predictive for hepatic veno-occlu-
ive disease [1-9]. Performance status as deﬁned by the
arnofsky or Zubrod scales for adult patients or the
ansky scale for pediatric patients represents a sim-
liﬁed tool of functional assessment and does not
ccount for the presence or absence of speciﬁc comor-
idities [10,11]. Performance status has been exten-
s
a
s
d
a
b
o
u
i
p
T
i
i
p
m
c
t
i
A
w
m
a
C
w
c
w
t
h
P
t
r
m
l
m
P
C
t
t
p
C
c
l
h
(
f
p
a
2
t
.
y
C
s
p
s
a
p
r
o
[
w
s
C
C
S
m
d
s
c
o
t
p
a
t
l
t
i
A
d
i
a
T
B
H
O
G
C
O
R
E
A
P
H
A
C
I
D
C
P
H
O
I
R
P
R
P
P
H
P
Measures of Morbidity 99ively explored as a prognostic factor for outcomes
fter progenitor cell transplantation, with most large
eries of allogeneic and autologous transplantations
emonstrating that nonrelapse mortality and survival
re related to performance status [12-14]. However,
ecause very few patients with performance status 2
r Karnofsky score 70 undergo transplantation, the
tility of performance status as a discriminator is lim-
ted.
Comorbidity indices have been developed and ap-
lied to a wide variety of medical conditions [15-18].
hese tools appear to be useful for intervention stud-
es and as a prognostic aid for clinicians and are
mportant factors to consider when comparing or
erforming clinical trials. The use of standard co-
orbidity indices as predictors of transplantation out-
omes or as instruments to allocate patients to speciﬁc
ransplantation therapies has only recently been stud-
ed in certain detail. Shahjahan et al [19] at MD
nderson retrospectively analyzed a cohort of patients
ith AML and myelodysplastic syndrome to deter-
ine the effect of comorbidities on the outcome of
llogeneic HSCT. They used an adaptation of the
harlson Comorbidity Index (CCI) to obtain a
eighted composite score for all pretransplantaiton
omorbid conditions. In their analysis of 78 patients
ith AML in ﬁrst remission, the researchers reported
hat higher CCI scores (2 versus 0-2) correlated with
igher nonrelapse mortality at 100 d (14% versus 3%,
 .08) and at 1 yr (26% versus 4%, P  .03) after
ransplantation [19]. Sorror et al [20] reported their
esults of a retrospective analysis of patients with he-
atologic malignancy who underwent matched unre-
ated HSCT after a myeloablative (n  74) or non-
yeloablative (n  60) conditioning regimen.
retransplantation comorbidities also were scored per
CI in that study. The investigators concluded from
heir analysis that higher CCI score before transplan-
ation was an independent risk factor for higher trans-
lant-related toxicity and nonrelapse mortality [20].
Sorror et al [21] compared the performance of the
CI and the Kaplan-Feinstein scale in predicting out-
omes after reduced intensity ﬂudarabine and melpha-
an transplantation in 81 patients with a variety of
ematologic malignancies. Median age was 51 yr
range, 17-68 yr) and 55% of patients received cells
rom an HLA-identical sibling donor. In total, 53% of
atients scored 1 point for a comorbid condition as
ssessed by the Kaplan-Feinstein scale compared with
5% by CCI (P  .001) and 28% scored 2 points by
he Kaplan-Feinstein scale versus 8% by CCI (P 
001). Comorbidity, performance status, and age 50
r predicted increased nonrelapse mortality [21].
Sorror et al recently reported a reﬁnement of the
CI to account for some transplant-speciﬁc factors
uch as prior infection. This modiﬁed CCI segregated
atients into 3 risk categories for TRM. Patients with
Hcores of 0, 1-2, and2 had TRM rates of 13%, 24%,
nd 40%, respectively. When the score was applied to
atients receiving nonablative or ablative conditioning
egimens, the TRM rate was signiﬁcantly different
nly in patients with scores 3 (17% versus 27%)
22]. Recently this scoring system has been validated
ith data from patients with AML or myelodysplastic
yndrome in remission from MD Anderson Cancer
enter and the Fred Hutchinson Cancer Research
enter [23]. Elements of the Seattle Comorbidity
core are summarized in Table 1.
Traditionally transplantation outcomes have been
easured primarily as survival, event-free survival, or
egree of organ toxicities, with most quality-of-life
tudies limited to long-term follow-up studies. Re-
ently comprehensive prospective longitudinal studies
f symptom burden after transplantation have opened
he door for a potential new measurement of trans-
lantation outcome. Dr Anderson recently completed
study using the MD Anderson Symptom Inventory
o monitor symptoms in 109 patients with hemato-
ogic malignancies undergoing autologous blood
ransplantation or BMT using pencil-and-paper or
nteractive voice recording technology. The MD
nderson Symptom Inventory ratings were obtained
uring BMT and up to 1 yr thereafter. Symptom
ntensities reached their highest levels at the nadir
ssessment and then gradually decreased, returning to
able 1. Elements of the Seattle Comorbidity Scoring System
Comorbidity Weighted Score
leeding
eadache
steoarthritis
astrointestinal disease
oagulopathy
steoporosis
enal, mild
ndocrine disease
sthma
ulmonary, mild
ypertension
rrhythmia 1
ardiac 1
nflammatory bowel disease 1
iabetes 1
erebrovascular disease 1
sychiatric disturbance 1
epatic, mild 1
besity 1
nfection 1
heumatologic 2
eptic ulcer 2
enal, moderate/severe 2
ulmonary, moderate 2
rior solid tumor 3
eart valve disease 3
ulmonary, severe 3
epatic, moderate/severe 3
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S. Giralt et al.100aseline by day 30 after transplantation with exception
f nausea, lack of appetite, weakness, and feeling phys-
cally sick, whereas intensities of pain, distress, and
adness at day 30 were signiﬁcantly lower than at
aseline [24].
SSESSING PHYSICAL FUNCTION IN PATIENTS WITH
ANCER: WHAT ARE THE MEASUREMENTS AND
HAT DO THEY MEAN?
BMT/PBSCT represents the treatment of
hoice for many patients with hematologic cancers
nd some solid tumors. These procedures are being
erformed with increasing frequency and success.
hat was once a salvage procedure for patients with
esistant and end-stage malignancies is now gener-
lly performed earlier in the disease course and
ong-term survival has resulted from better under-
tanding and management of the disease, the treat-
ents, and the side effects of both. Despite the
eneﬁts associated with BMT, eg, improved re-
apse-free survival, there are also numerous associ-
ted sequelae, such as pancytopenias, fatigue, and
ardiopulmonary toxicities, that may limit patients’
unction and activities. These health problems com-
romise physical function, thereby adding to dis-
ress and disease burden for patients and their fam-
lies. Because long-term survival is now a reality, it
s important to focus on the quality of that survival,
e, enhancing quality of life and of living with a
hronic and potentially fatal disease.
Through its focus on symptom management (pain
nd fatigue) and improvement in physical function,
ehabilitation plays an important role in the manage-
ent of patients after BMT. Optimal management of
unction is predicated on a sound, comprehensive as-
essment using psychometrically sound (valid and re-
iable) assessment tests. In recent years standardized
erformance-based tests have been developed and
sed in patients with a variety of chronic health con-
itions including those with cancers. Standardized
ests of physical performance quantify task perfor-
ance and complement patient self-reports of func-
ion. Different performance test batteries have been
eveloped for and tested in different patient groups.
ased on simple measurements of time taken or dis-
ance covered, these task batteries have clinical utility
nd excellent psychometric properties. They are used
o assess the magnitude and burden of physical dys-
unction, predict outcome including survival, identify
he factors that limit physical performance (eg, pain,
atigue, fear, muscle weakness), and guide and deter-
ine the effectiveness of treatment protocols. Perfor-
ance tests are sensitive to improvement after reha-
ilitation, are good predictors of long-term (5-yr)
urvival, and may be sensitive to change in disease
tatus. mFive functional tests have been validated in pa-
ients with and without cancer, are relatively easy to
erform in a short period, and are easily reproducible;
hese are summarized in Table 2 [25-27].
EVERSING FRAILTY AND IMPROVING
UNCTIONAL STATUS
otential roles for growth hormone secretagogues
n progenitor cell transplantation
Growth hormone (GH) is a 191-amino acid pep-
ide that is synthesized and secreted by the anterior
ituitary gland in pulsatile fashion [28,29]. GH has
nabolic, lipolytic, and antinatriuretic actions. GH
lays a vital role in normal growth and development
nto adulthood. GH secretion decreases in the third
ecade of life. This decrease in GH secretion has been
ostulated as a contributing cause of the aging phe-
otype. There has been signiﬁcant interest in treat-
ent of elderly persons with recombinant human GH
n hopes that the anabolic properties of GH could halt
r reverse the age-related catabolic state and its re-
ultant physical changes [30,31].
Rudman et al [32] were the ﬁrst to study the
ffects of recombinant human GH in a group of men
60 yr of age with low baseline levels of insulinlike
rowth factor I (IGF-I). After 6 mo of therapy, plasma
GF-I levels were restored to youthful levels, lean
ody mass increased by 8%, fat mass decreased by
4%, and lumbar vertebral bone density increased by
.6% [32]. Studies in postmenopausal women have
ot produced such promising results, with a signiﬁ-
ant number of women developing intolerable side
ffects [33]. The adverse side effects of GH and the
eed for parenteral administration have led to the
evelopment of GH-releasing peptides and GH secre-
agogues. Two such compounds that have been ex-
lored in the clinic and have been shown to elicit GH
ecretion in ways similar to GH-releasing peptides are
-692,429 and MK-677 [34].
MK-0677 has been administered to healthy young
able 2. Measurements of Functional Status
Test
Cancer
Patient/Control
Comments30-59 yr >59 yr
oin test 6.7/3.9 8.5/5.5 Time to pick up 4 coins
ock test 9.0/5.1 10.3/7.0 Time to put on a loose-
fitting sock
0-ft walk 15.9/9.2 30.3/11.6 Time to walk 50 ft at a
comfortable pace
it to stand 8.0/2.8 9.0/4.0 Time to stand up and sit
down again from a chair
-min walk (m) 320/602 240/465 Distance walked during 6
min at comfortable paceen subjected to short-term diet-induced nitrogen
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Measures of Morbidity 101asting. Treatment with MK-0677 produced a sus-
ained increase in serum concentrations of GH and
GF-I and reversal of nitrogen wasting when given to
ealthy obese males once daily with 25 mg MK-0677
or 8 wk. Increased basal metabolic rate was observed
fter 2 wk but not after 4 wk of treatment. Dual energy
-ray absorptiometry showed that weight gain was
xplained by an increase in fat-free mass [35,36].
Because GH stimulates bone turnover and acti-
ates osteoblast activity, it was postulated that admin-
stration of MK-0677 plus an inhibitor of bone resorp-
ion would increase the rate of bone formation. The
ffects of MK-0677, alone and in combination with
he bisphosphonate alendronate, were evaluated dur-
ng 12 and 18 mo of treatment in a multicenter,
andomized, double-blind, placebo-controlled study.
total of 292 women (64-85 yr old) with low femoral
eck bone mineral density (BMD) participated in the
tudy. The combination of MK-0677 and alendronate
ncreased bone formation compared with alendronate
lone, reduced the effect of alendronate on resorption
NTx), and increased BMD at the femoral neck by
.2% compared with 2.5% with alendronate alone
P  .05). However, the combination did not enhance
MD of the lumbar spine, total hip, or total body
eyond that achieved with alendronate alone [37].
The potential beneﬁts of MK-0677 on recovery
fter hip fractures were explored in a placebo-con-
rolled, randomized, double-blind trial. In total, 161
atients with hip fracture were recruited at 3-14 d
fter surgery. Patients with multiple fractures, severe
rauma, diabetes mellitus, cancer, uncontrolled hyper-
ension, congestive heart failure, or total hip replace-
ent in the involved extremity were excluded. Pa-
ients were randomly assigned to daily treatment with
K-0677 or placebo for 6 mo and then followed for
n additional 6 mo after completing therapy There
ere no signiﬁcant changes between MK-0677 and
lacebo in improving functional performance mea-
urements or in the overall SIP-NH score, but MK-
677-treated patients showed greater improvement
ompared with placebo in 3 of 4 lower extremity
unctional performance measurements, in the physical
omain of the SIP-NH, and in the ability to live
ndependently [38].
These studies show the potential beneﬁts and lim-
tations of the currently available GH secretogogues
s potential enhancers of functional status during
igh-dose chemotherapy regimens. Notwithstanding
he anabolic effects of these agents, their immunologic
ffects warrant prospective studies in the setting of
igh-dose chemotherapy particularly in the high-risk
lderly or debilitated patient.
In the lay media there has been an explosion of
ubstances claiming to be GH secretagogues and are
old as health food supplements. The primary com-
onents of these formulations are arginine and glu-amine, which stimulate GH secretion. None of these
upplements have been studied in randomized con-
rolled trials; however, in a randomized, double-blind,
lacebo-controlled trial in healthy postmenopausal
omen, daily oral ingestion of 9 g of arginine signif-
cantly increased GH secretion, without affecting in-
ulin, catecholamines, and serum lipids [39].
UMMARY
As high-dose therapy is performed in more elderly
nd debilitated patients, the potential deterioration in
uality of life and functional independence after ther-
py may be higher. These outcomes are not routinely
easured and are now becoming important aspects of
rogenitor cell transplantation research. In determin-
ng the prognostic value of comorbidities, functional
ssessment tools will be an important ﬁrst step in
esigning intervention and prevention trials with an-
bolic agents or anti-inﬂammatory cytokines. This
rea is a ﬁeld in which transplantation specialists can
eneﬁt from close collaborations with geriatricians,
ehabilitation medicine specialists, endocrinologists
nd physical therapists.
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